Modification at the C9 position of the marine natural product isoaaptamine and the impact on HIV-1, mycobacterial, and tumor cell activity

A series of isoaaptamine analogs were prepared at the C9 position of isoaaptamine ( 2) and were evaluated for their biological activity against HIV-1, Mtb, AIDS-OI, tropical parasitic diseases, and cancer. As part of an investigation to generate optimized drug leads from marine natural pharmacophore...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry Vol. 14; no. 24; pp. 8495 - 8505
Main Authors Gul, Waseem, Hammond, Nicholas L., Yousaf, Muhammad, Bowling, John J., Schinazi, Raymond F., Wirtz, Susan S., de Castro Andrews, Garcia, Cuevas, Carmen, Hamann, Mark T.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 15.12.2006
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A series of isoaaptamine analogs were prepared at the C9 position of isoaaptamine ( 2) and were evaluated for their biological activity against HIV-1, Mtb, AIDS-OI, tropical parasitic diseases, and cancer. As part of an investigation to generate optimized drug leads from marine natural pharmacophores for the treatment of neoplastic and infectious diseases, a series of novel isoaaptamine analogs were prepared by coupling acyl halides to the C9 position of isoaaptamine ( 2) isolated from the Aaptos sponge. This library of new semisynthetic products was evaluated for biological activity against HIV-1, Mtb, AIDS-OI, tropical parasitic diseases, and cancer. Compound 4 showed potent activity against HIV-1 (EC 50 0.47 μg/mL), compound 19 proved to possess remarkable activity against Mycobacterium intracellulare with an IC 50 and MIC value of 0.15 and 0.31 μg/mL, while compounds 4 and 17 possessed anti-leishmanial activity with IC 50 values of 0.1 and 0.4 μg/mL, respectively. Compounds 16 and 17 showed antimalarial activity with EC 50 values of 230 and 240 ng/mL, respectively, and compound 14 exhibited an EC 50 of 0.05 μM against the Leukemia cell line K-562.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2006.08.042